Drug Retail
featured
CAMP HILL, Pa.-- Rite Aid's revenue from stores open at least a year fell 2 percent in March, as cheaper generic drugs continued to hurt the drugstore operator's performance. Rite Aid Corp., which is based in Camp Hill, Pa., had 4,621 stores as of March 30. In morning trading, Rite Aid shares slipped 4 cents, or 2.3 percent, to $1.71.
» Read MoreMore
-
CAMP HILL, Pa.-- Rite Aid's revenue from stores open at least a year fell 2 percent in March, as cheaper generic drugs continued to hurt the drugstore operator's performance. Rite Aid Corp., which is based in Camp Hill, Pa., had 4,621 stores as of March 30. In morning trading, Rite Aid shares slipped 4 cents, or 2.3 percent, to $1.71.
-
Johnson & Johnson just won approval for a new diabetes drug, and the stock is at an all-time high today. Anthony Butler, Barclays, offers insight.
-
Drugstore operator CVS Caremark Corp.' s board of directors has elected former Johnson& Johnson Chairman and CEO William C. Weldon to join the board. CVS Caremark has more than 7,400 drugstores and runs one of the nation's largest pharmacy benefits management businesses.
-
Biotech has returned 20 percent for investors this year. Biogen IDEC CEO George Scangos, discusses the recent FDA approval of his company's drug, which is its first pill for multiple sclerosis.
-
March 26- The International Council of Shopping Centers and Goldman Sachs on Tuesday released the following seasonally adjusted weekly data on U.S. chain store retail sales. ICSC Research said it expects March same-store sales to rise between 5.0 and 5.5 percent excluding drug store sales, due partly to an earlier Easter holiday this year.
-
The government says big pharma should not be allowed to pay generic drug makers to let them keep their costly branded drugs on the market longer, reports CNBC's Bertha Coombs.
-
CNBC's Seema Mody reports the latest from the Nasdaq: Drug makers Actavis and AstraZeneca reach an agreement to launch a Crestor generic in 2016.
-
AstraZeneca settled a patent dispute with generic drug maker Watson Laboratories over its cholesterol drug Crestor, reports CNBC's Bertha Coombs.
-
One sector that is yet to be truly tapped in Africa is the brewing industry, according to research firm Bernstein Research, which believes it is probably the most attractive region for long-term profit growth for global brewers.
-
**AMERISOURCEBERGEN, Monday close $51.27, up 6 pct premarket. Drug distributor AmerisourceBergen signed a 10- year distribution deal with Walgreen Co and partner Alliance Boots ABN.UL that it said would deliver $28 billion in incremental revenue in fiscal 2014 and give the pharmacy chains the right to acquire up to 23 percent of the company.
-
March 19- Drug distributor AmerisourceBergen signed a 10- year distribution deal with Walgreen Co and partner Alliance Boots that it said would deliver $28 billion in incremental revenue in fiscal 2014 and give the pharmacy chains the right to acquire up to 23 percent of the company.
-
March 19- The International Council of Shopping Centers and Goldman Sachs on Tuesday released the following seasonally adjusted weekly data on U.S. chain store retail sales. ICSC Research said it expects March same-store sales to rise between 5 and 6 percent excluding drug store sales, due partly to an earlier Easter holiday in 2013..
-
Sometimes, when a stock surges on an analyst upgrade, it's high time to make a bearish bet. That's exactly what one big options trader did on Walgreen.
-
March 11- Walgreen Co has been sued by a California woman who accused the largest U.S. drugstore chain of deceiving customers into believing its Vitamin E dietary supplement contributes to cardiovascular health.
-
After a difficult January, when shoppers first felt the effect of a payroll tax hike that lowered take-home pay by 2 percent, some retailers got a little relief in February from growing employment and a rising stock market.
-
Containing health care costs, promoting innovation and the treatment of deadly diseases are among the biggest challenges the U.S. faces, Johnson and Johnson CEO Alex Gorsky said on Thursday.
-
Moves by Indonesia's President Susilo Bambang Yudhoyono to put his finance minister in charge of the central bank is leading to concerns that he may be seeking someone more malleable to run the state coffers in the run up to next year's elections.
-
The pharmaceutical and biopharmaceutical sectors have been marching steadily higher. TheStreet.com reports on two stocks with potential to appreciate.
-
Mylan's aquisition of Agila is expected to double its business. Heather Bresch, Myland CEO, offers insight.
-
CNBC's Brian Shactman reports the Department of Justice is joining Floyd Landis in a lawsuit accusing Lance Armstrong using performance-enhancing drugs while being sponsored by the U.S. Postal Service. Armstrong says he did not cost the government money. Instead, he says the Postal Service actually benefitted to the tune of more than $100 million from its association with the disgraced cyclist.